Trifluridine/tipiracil plus bevacizumab group | Trifluridine/tipiracil monotherapy group | ||||
---|---|---|---|---|---|
N = 60 | % | N = 66 | % | ||
Age | Median (range) | 60 (23–79) | 65 (30–80) | ||
≥65 years old | 19 | 31.7 | 34 | 51.5 | |
Gender | Male | 35 | 58.3 | 42 | 63.6 |
ECOG PS | 0 | 35 | 58.3 | 42 | 63.6 |
1 | 24 | 40.0 | 21 | 31.8 | |
2 | 1 | 1.7 | 3 | 4.5 | |
Primary location | Right | 11 | 18.3 | 10 | 15.2 |
Left | 49 | 81.7 | 56 | 84.8 | |
Number of metastatic organs | 1 | 6 | 10.0 | 13 | 19.7 |
2 | 26 | 43.3 | 39 | 59.1 | |
≥3 | 28 | 46.7 | 14 | 21.2 | |
Time from start of first-line chemotherapy | < 18 months | 22 | 36.7 | 23 | 34.8 |
≥18 months | 38 | 63.3 | 43 | 65.2 | |
Time from prior bevacizumab | ≤1 month | 34 | 56.7 | 33 | 50.0 |
> 1 month or no prior bevacizumab | 26 | 43.3 | 33 | 50.0 | |
Number of prior regimens | 1 | 4 | 6.7 | 2 | 3.0 |
2 | 29 | 48.3 | 33 | 50.0 | |
3 | 15 | 25.0 | 16 | 24.2 | |
≥4 | 12 | 20.0 | 15 | 22.7 | |
Prior chemotherapy agents | Fluoropyrimidine | 60 | 100 | 66 | 100 |
Irinotecan | 60 | 100 | 66 | 100 | |
Oxaliplatin | 60 | 100 | 66 | 100 | |
Angiogenesis inhibitors | 58 | 96.7 | 61 | 92.4 | |
Anti-EGFR antibodies | 27 | 45.0 | 27 | 40.9 | |
RAS status | Wild-type | 28 | 46.7 | 30 | 45.5 |
Mutant | 32 | 53.3 | 36 | 54.5 | |
BRAF status | Wild-type | 52 | 86.7 | 52 | 78.8 |
V600E mutant | 1 | 1.7 | 4 | 6.1 | |
Non-V600E mutant | 2 | 3.3 | 0 | 0 | |
Unknown | 5 | 8.3 | 10 | 15.2 | |
MSI status | MSS | 53 | 88.3 | 51 | 77.3 |
Unknown | 7 | 11.7 | 15 | 22.7 |